Subscribe to Search results

Dr Colvin reported that, at London Hospital Haemophilia Centre, there were 41 patients infected with HIV, of whom 31 had severe Haemophilia A, 9 had moderate/mild Haemophilia A and 1 had Haemophilia B. He recalled three children who were infected with HIV from their treatment and one partner of a patient who was infected.

Published on:

Whilst the volume of NHS concentrate used at the Leeds Haemophilia Centre increased in 1983, a very substantial amount of commercial concentrate continued to be used.

Published on:

1,497,585 units of NHS Factor 8 and 1,715,894 units of commercial concentrates were used at the Leeds Haemophilia Centre.

Published on:

Small amounts of cryoprecipitate were used with NHS concentrate and commercial concentrates were used in substantial amounts at the Leeds Haemophilia Centre.

Published on:

At a Mersey RTC meeting, there was no discussion at all about the issue of AIDS.

Published on:

In Liverpool, the use of NHS concentrate increased in 1983.

Published on:

In Liverpool, the use of NHS concentrate increased in 1984.

Published on:

Dr McVerry indicated that he had no awareness of AIDS until the September 1982 UKHCDO meeting. Up to mid 1984, there was no proven association with blood products, although he said it was reasonably clear there was a real risk at the end of 1983 or beginning of 1984.

Published on:

Dr McVerry could not recall giving cryoprecipitate to a patient in Liverpool.

Published on:

Dr McVerry stated he "was encouraged to switch to commercial F8 for two reasons". Availability and reliability of supply, and the general policy to keep an individual patient on one specific product to reduce prevalence of factor antibodies arising

Published on:

The purchase of commercial Factor 8 concentrates was undertaken via the Royal Liverpool Hospital, in part because the district health authority was able to get a better price per unit by buying in bulk, and supplied by the Royal Liverpool's haemophilia ward to Alder Hey.

Published on:

Professor Hay stated that "all patients were treated with whichever material was available. No cohorts were treated with any specific product". He stated insufficient use of cryoprecipitate was used.

Published on:

When Professor Hay arrived in Liverpool he found records to be poor and uninformative and was unable to obtain the results of the tests that had been carried out. He was told by patients that they were informed of HIV positive results by letter.

Published on:

Other documentation arising in the context of litigation suggests that "no specific priority was given to mild haemophiliacs for treatment with NHS product at the time."

Published on:

Information from legal claims relating to other children treated at Alder Hey reveal the appropriate approach to treatment.

Published on:

A child with severe haemophilia was regularly treated at Alder Hey with concentrate, "at least some of it commercial after mid-1983."

Published on:

A child with mild haemophilia had received commercial Factor VIII for a tooth extraction. This treatment "would not seem to be justified."

Published on:

A child born in 1980 (inferentially with severe haemophilia) "received a substantial amount of concentrate, the majority of it being commercial concentrate. The type of concentrate would have been dependant upon availability and treatment was standard." It was said that there was "Nothing atypical about treatment given to this Plaintiff."

Published on:

Another child with mild haemophilia was treated with what appeared to be NHS Factor 8 in late 1982 and commercial Factor 8 between March and July 1983.

Published on:

A patient with mild/moderate haemophilia was treated with concentrates for elective surgery. The notes lacked detail to identify products used but "Dr Martin's statement confirms that no distinction was made at Alder Hey Hospital in terms of which product to prefer" vs what was available.

Published on: